Alpha 1 Antitrypsin Deficiency Treatment
SKU
MRR-C002B1C99847
Region
Global
Publication Date
February 2024
Delivery
Immediate
2023
USD 3.02 billion
2030
USD 5.57 billion
2024
USD 3.26 billion
CAGR
9.15%
Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment (Augmentation Therapy, Bronchodilators, Corticosteroids), Route of Administration (Inhalation, Injection, Oral), Distribution Channel - Global Forecast 2024-2030

[184 Pages Report] The Alpha 1 Antitrypsin Deficiency Treatment Market size was estimated at USD 3.02 billion in 2023 and expected to reach USD 3.26 billion in 2024, at a CAGR 9.15% to reach USD 5.57 billion by 2030.

Alpha 1 Antitrypsin Deficiency Treatment Market
To learn more about this report, request a free sample copy
Alpha 1 Antitrypsin Deficiency (AATD) is a genetic disorder that results in reduced or no production of the alpha 1 antitrypsin (AAT) protein, which is vital for protecting the lungs from the harmful effects of enzymes such as neutrophil elastase. It generally includes augmentation therapy using AAT from blood donors, medications to treat respiratory symptoms, and lung or liver transplants in severe cases. Drivers include the increasing prevalence of the disorder, advancements in genetic testing facilitating early diagnosis, and the development of new and more effective therapies. High costs associated with therapies and the limited availability of donor AAT proteins are restraining factors. Moreover, there can be challenges related to the reimbursement policies for treating AATD. One of the primary challenges is the underdiagnosis or misdiagnosis of the condition, given its rare nature and the commonality of its symptoms with other respiratory diseases. There is also a challenge in ensuring sufficient production and supply of augmentation therapy products to meet global needs. Opportunities include the growing investment in research and development of gene therapy as a potential curative treatment and the expansion of reimbursement policies. Emerging markets also present new opportunities due to increasing healthcare infrastructure and rising economic standards.
Alpha 1 Antitrypsin Deficiency Treatment Market - Global Forecast 2024-2030
To learn more about this report, request a free sample copy
FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alpha 1 Antitrypsin Deficiency Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alpha 1 Antitrypsin Deficiency Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alpha 1 Antitrypsin Deficiency Treatment Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc, Alnylam Pharmaceuticals, Inc., Apic Bio, Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Cedars-Sinai Health System, Centessa Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., CSL Limited, Curaxys S.L., Dicerna Pharmaceuticals, Inc, GlaxoSmithKline PLC, Grifols, S.A., Inhibrx, Inc., Intellia Therapeutics, Inc., Kamada Ltd., Krystal Biotech, Inc., LFB Biomedicaments S.A., Mereo Biopharma Group PLC, Novo Nordisk A/S, Pfizer, Inc., PH PHARMA CO. LTD, Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Alpha 1 Antitrypsin Deficiency Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Augmentation Therapy
    • Bronchodilators
    • Corticosteroids
    • Oxygen Therapy
  • Route of Administration
    • Inhalation
    • Injection
    • Oral
  • Distribution Channel
    • Offline
      • Hospital Pharmacy
      • Retail Pharmacy
    • Online

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Alpha 1 Antitrypsin Deficiency Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alpha 1 Antitrypsin Deficiency Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Alpha 1 Antitrypsin Deficiency Treatment Market?
  4. What is the market share of the leading vendors in the Alpha 1 Antitrypsin Deficiency Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Alpha 1 Antitrypsin Deficiency Treatment Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Alpha 1 Antitrypsin Deficiency Treatment Market, by Treatment
  7. Alpha 1 Antitrypsin Deficiency Treatment Market, by Route of Administration
  8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel
  9. Americas Alpha 1 Antitrypsin Deficiency Treatment Market
  10. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market
  11. Europe, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market
  12. Competitive Landscape
  13. Competitive Portfolio
Companies Mentioned
  • Abeona Therapeutics Inc
  • Alnylam Pharmaceuticals, Inc.
  • Apic Bio
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Cedars-Sinai Health System
  • Centessa Pharmaceuticals PLC
  • Chiesi Farmaceutici S.p.A.
  • CSL Limited
  • Curaxys S.L.
  • Dicerna Pharmaceuticals, Inc
  • GlaxoSmithKline PLC
  • Grifols, S.A.
  • Inhibrx, Inc.
  • Intellia Therapeutics, Inc.
  • Kamada Ltd.
  • Krystal Biotech, Inc.
  • LFB Biomedicaments S.A.
  • Mereo Biopharma Group PLC
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • PH PHARMA CO. LTD
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Alpha 1 Antitrypsin Deficiency Treatment Market
The Global Alpha 1 Antitrypsin Deficiency Treatment Market size was estimated at USD 3.02 billion in 2023 and expected to reach USD 3.26 billion in 2024.
The Global Alpha 1 Antitrypsin Deficiency Treatment Market to grow USD 5.57 billion by 2030, at a CAGR of 9.15%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.